1. Introduction {#s0005}
===============

The synthesis of acute-phase proteins is largely regulated by inflammation-associated cytokines, peptide hormone signals produced by endothelial cells, lymphocytes, and activated monocytes/macrophages. Serum amyloid A (SAA) is a generic term for a family of acute-phase proteins coded for by different genes with a high degree of homology in mammals [@b0005; @b0010].

In humans and mice, *SAA1* and *SAA2* genes are best characterized sharing approx. 95% overall sequence identity [@b0015; @b0020]. The different alleles of the *SAA1/2* loci encode non-glycosylated acute-phase SAA (A-SAA) 1/2 proteins (104-amino acids \[*aa*\], 12-kDa). A-SAA may reach plasma levels 1000-fold greater than that found in the non-inflammatory state, thus representing an ideal marker for clinical use [@b0025]. A-SAA acts as precursor protein for reactive systemic amyloid A (AA) amyloidosis [@b0030] and modulates the atheroprotective properties of high-density lipoproteins (HDL) during inflammation [@b0035]. Other activities, e.g. interaction with various receptors that modulate cytokine release and intracellular signalling pathways, activation of transcription factors and production of matrix metalloproteinases, underline a potential role of A-SAA in atherogenesis, coronary syndrome, and tumor pathogenesis [@b0040; @b0045; @b0050]. While human *SAA3* (*hSAA3*) is considered a pseudogene, the murine *Saa3* (*mSaa3*) homolog codes for mSAA3 protein.

In humans and mice, the *SAA4* locus contains the gene encoding for a unique SAA family member assumed to be constitutively expressed [@b0055; @b0060]. The *SAA4* gene differs from *SAA1/2*, whose four exons and three introns share in between 93 and 100% and 87 and 92% identity. The hSAA4 protein (14-kDa) shares approx. 55% identity with SAA1/2. Due to an octapeptide insertion, hSAA4 consists of 112-*aa*. A N-linked glycosylation site in this octapeptide may lead to an additional 19-kDa protein [@b0055]. Under physiological conditions hSAA4 constitutes more than 90% of total SAA [@b0065]; it associates with very low-density lipoproteins and HDL [@b0065]. In contrast to A-SAA, SAA4 does basically not act as the precursor molecule for AA fibrils, and levels do not change dramatically during the acute-phase response [@b0070].

Contrary to all mammalian species studied, the rat lacks expression of A-SAA proteins [@b0075]. Consequently, rats do not develop AA amyloidosis [@b0075], a disease in which fibrils formed from the 76-*aa* N-terminal portion of A-SAA induce severe organ dysfunction.

We here present first evidence on characterization of mRNAs for rat *SAA4* (*rSAA4*), abundant expression of rSAA4 in the liver on mRNA and protein level, and its cellular localization.

2. Materials and methods {#s0010}
========================

2.1. Rapid amplification of cDNA ends (RACE) {#s0015}
--------------------------------------------

Rat brain Marathon-Ready cDNA (Clontech Laboratories, Takara Bio Company, Mountain View, CA) was used as template to amplify full-length *rSAA4* cDNA ([Supplemental Table I](#s0090){ref-type="sec"}). Primers used for the amplification of the 5′ and 3′cDNA ends are given in [Supplemental Table II](#s0090){ref-type="sec"}. RACE products were cloned into a pCR®2.1-Topo® vector (Life-Technologies Ltd., Invitrogen, Paisley, UK) and transformed into TOP10 One Shot® Cells (Life-Technologie). After transformation plasmid DNA was isolated using Qiagen Plasmid Mini Kit (Qiagen, Hilden, Germany) and sequenced with vector-specific M13 and *rSAA4*-specific primers ([Supplemental Table II](#s0090){ref-type="sec"}). After dye terminator removal with Centri-Sep spin columns (Princeton Separations, Freehold, NJ) sequencing reactions were analyzed with a 3100 Genetic Analyzer (Life-Technologies™, Foster City, CA).

2.2. RNA isolation, DNase-I digestion and reverse-transcription {#s0020}
---------------------------------------------------------------

Sprague--Dawley rats (200--300 g body weight; Himberg, Austria) received an i.p. injection of 2 mg/kg LPS (*Escherichia coli*, Serotype 055:B5; Sigma--Aldrich, St. Louis, MO) or vehicle (PBS). The study was approved by the ethics committee of the Federal Ministry of Science, Austria \[GZ 66.010/9-Pr/4/2002\] carried out in line with the European Communities Council Directive. After 48 h rats were killed with an overdose of sodium pentobarbital and tissues were kept either in N~2~ or at 25 °C (in case of pancreas, colon, and lungs) in 1 ml RNA Later Reagent (Life-Technologies). Using Trizol reagent (Life-Technologies) or RNeasy-Minikit (Qiagen) total RNA was isolated from rat tissues and McA-RH7777 cells. One μg of RNA was digested with DNase-I and reverse-transcribed using random hexamer primers and SuperScript® II Reverse Transcriptase (Life-Technologies) [@b0080].

2.3. qPCR-analysis {#s0025}
------------------

qPCR-assays were performed using Power SybrGreen Mastermix, ABI Prism 7000 SDS instrument (Life-Technologies) and respective primers ([Supplemental Table III](#s0090){ref-type="sec"}). Fold-change in gene expression of the target gene compared to *rGAPDH* was calculated by the 2^−ΔΔCT^ method and absolute mRNA expression (copy number) was determined by the equation of a calibration curve.

2.4. Protein isolation and Western blot analysis {#s0030}
------------------------------------------------

Frozen rat tissues were immersed in extraction buffer ([Supplemental Table IV](#s0090){ref-type="sec"}) and homogenized with Ultraturrax (Ika GmbH, Staufen, Germany). Lysates were centrifuged and supernatants were subjected to Western-blot analysis [@b0080]. Membranes were incubated with anti-human SAA4 peptide (*aa*-position 94--112) rabbit antiserum (dilution 1:2500) [@b0085]. As positive controls, hSAA4 [@b0090] and tagged-hSAA4 [@b0085] (both expressed in *E. coli*) were used.

2.5. Cell culture experiments {#s0035}
-----------------------------

McA-RH7777 hepatoma cells (ATCC) were grown in DMEM ([Supplemental Table IV](#s0090){ref-type="sec"}) at 37 °C in 5% CO~2~. Cells, seeded in 6-well plates, were incubated in DMEM containing 10 ng/ml IL-1α/β, IL-6, TNFα (R&D Systems Inc., Minneapolis, MN) or 1 μg/ml LPS (Sigma--Aldrich) for 12--60 h.

2.6. Cloning of rSAA4pcDNA3.1/CT-GFP-TOPO vector and transfection of McA-RH7777 cells {#s0040}
-------------------------------------------------------------------------------------

To obtain a full-length rSAA4-GFP fusion protein a PCR was performed using *rSAA4*-cloning primers including the native Kozak-sequence ([Supplemental Table V](#s0090){ref-type="sec"}) and rat liver cDNA as template ([Supplemental Table VI](#s0090){ref-type="sec"}). The PCR-product was separated by gel electrophoresis and purified using Wizard SV Gel- and PCR-Clean-Up System (Promega, Madison, WI).

cDNA for *rSAA4* was cloned into pcDNA3.1/CT-GFP-TOPO vector (Life-Technologies) and McA-RH7777 cells (seeded on glass plates in 6-well-dishes, 70% confluence) were transfected using ExGen-500 in vitro Transfection Reagent (Fermentas, St. Leon-Rot, Germany). After 6 h, 1 ml of culture medium was added and incubated for 20 h.

2.7. Confocal imaging {#s0045}
---------------------

Cells were incubated with 1 ml of a loading solution ([Supplemental Table IV](#s0090){ref-type="sec"}) containing 0.5 μM ER-Tracker® Red or 0.1 μM Mito-Tracker® Red (Life Technologies Ltd.) for 5 or 40 min. GFP signals were imaged together with ER-Tracker® Red or Mito-Tracker® Red using a *Nipkow*-disk-based array confocal laser scanning microscope ([Supplemental material section](#s0090){ref-type="sec"}).

2.8. Luciferase assay {#s0050}
---------------------

In silico analysis of *rSAA4* promoters was performed with the Genomatix software package version 7.0. Gene2promoter was used to search for vertebrate promoter sequences of *SAA4* and MatInspector to identify transcription factor binding sites and their position and orientation towards each other.

### 2.8.1. Mutagenesis of the full-length rSAA4 promoter fragment (fl-rSAA4) {#s0055}

The sequence +44 to −3293 bp relative to the transcription start codon of *rSAA4* was cloned in pGL3 Basic vector (Promega) to create fl-*rSAA4*. Primers were designed with 15 bp homologous to the multiple cloning site of pGL3 with restriction enzyme binding sites to enable cloning of the *rSAA4* promoter fragment into pGL3 ([Supplemental Table VII](#s0090){ref-type="sec"}).

PCR-amplification of the fl-*rSAA4* promoter fragment was performed using the BAC clone CH230-458A11 (BACPAC resources center, Oakland, CA) as template ([Supplemental Table VI](#s0090){ref-type="sec"}). The PCR-products were purified using the Nucleospin II kit (Macherey & Nagel GmbH & Co. KG, Düren, Germany) and ligated with the In-Fusion Dry-Down PCR-Cloning Kit (Clontech-Laboratories) to create the recombinant fl-*rSAA4* vector. After transformation positive clones were identified with colony-PCR, restriction analysis and DNA sequencing.

To test the activity of the three C/EBP-elements most proximal to the start codon a deletion of the BOX (C/EBP-element 1--3 flanked by FAST and HOXF binding sites, −889 to −1166 bp) was performed to create construct A. Mutagenesis was performed with the Phusion Site-Directed Mutagenesis Kit (Thermo-Fisher-Scientific, Rochester, NY). Linearized vector A was created via PCR ([Supplemental Tables VI and VIII](#s0090){ref-type="sec"}). The PCR-product was separated from unmutated, non-linearized template vector by agarose gel electrophoresis and isolated with the Nucleospin II Kit. For circularization, 20 ng linearized vector was ligated with T4 DNA-Ligase (Fermentas), transformed into *E. coli* Fusion-Blue cells (Clontech-Laboratories). Positive clones were identified by colony-PCR and DNA-sequencing.

### 2.8.2. Cloning of rSAA4 promoter fragments {#s0060}

Deletions constructs were created to further investigate the three proximal C/EBP- elements: B (+44 to −1084), C (+44 to −1113), D (+44 to −2449), and E (+44 to −932). Promoter fragments of *rSAA4* were PCR-amplified using the respective synthetic oligonucleotides ([Supplemental Table VII](#s0090){ref-type="sec"}) and the BAC-clone CH230-458A11 (BACPAC resources center) as template.

### 2.8.3. Luciferase reporter assay {#s0065}

Cells (80% confluence) were transfected with 2 μg of the respective pGL3 construct (expressing Firefly Luciferase) and 4 ng of the control plasmid pRL-TK (expressing Renilla Luciferase) using ExGen-500 in vitro Transfection Reagent (Fermentas) according to manufacturer's suggestion. Cells were lysed and Luciferase activity was measured using the dual-Luciferase reporter assay (Promega) on a luminometer (Lumat-LB9501, Berthold-Technologies GmbH & Co. KG, Bad Wildbad, Germany). To account for non-specific effects on reporter plasmids, experimental results were expressed as normalized ratios. The ratio of Renilla and Firefly-Luciferase activity of each experiment was normalized against cells transfected with the empty Luciferase vector.

2.9. Statistical analysis {#s0070}
-------------------------

Statistical analysis of qPCR data was performed by one-way ANOVA and of Luciferase-Assay by Student's *t*-test (unpaired, two-tailed). Means were considered as significantly different at *p* \< 0.05.

3. Results {#s0075}
==========

To determine the genomic structure of the *rSAA4* gene and the corresponding full-length *rSAA4* cDNA, we performed 5′- and 3′RACE using a rat cDNA library as template. These experiments showed an exon/intron organization for *rSAA4* consisting of one untranslated 5′exon followed by three translated exons ([Fig. 1](#f0005){ref-type="fig"}). The exon/intron organization of *rSAA4* is similar to that reported for *hSAA4* and *mSaa4* [@b0060; @b0095]. The 5′RACE experiments ([Fig. 1](#f0005){ref-type="fig"}C) in combination with reported ESTs (e.g. [FQ107900](ncbi-n:FQ107900){#ir010}, [Fig. 1](#f0005){ref-type="fig"}B) revealed that the maximal 5′UTR exceeds the reported RefSeq for *rSAA4* ([NM_001009478.1](ncbi-n:NM_001009478.1){#ir015}) by 90-bases ([Supplemental Table IA--C](#s0090){ref-type="sec"}). Within this region, we found a GA-dinucleotide tandem repeat with 23 repeats in the RefSeq sequence for *rSAA4* ([NM_001009478.1](ncbi-n:NM_001009478.1){#ir020}) ([Fig. 1](#f0005){ref-type="fig"}E and F). The sequence of this accession number is based on the cDNA clone MGC:108857.

Performing 3′RACE, we were able to reveal a maximum size of the 3′UTR of 1214-bases. This observation parallels the current version of *rSAA4* mRNA ([*BC088188*](ncbi-n:BC088188){#ir025}-[NM_001009478.1](ncbi-n:NM_001009478.1){#ir030}). We conclude that the full-length sequence of *rSAA4* mRNA consists of 1830-bases ([Supplemental Table IC](#s0090){ref-type="sec"}).

To test the possibility of a read-through transcription between *rSAA4* and the neighboring *HPS5* gene ([NM_001135612.1](ncbi-n:NM_001135612.1){#ir035}) indicated by the rat mRNA sequences *AY325132* and *AY325161* ([Fig. 1](#f0005){ref-type="fig"}A), a PCR spanning from the coding region of *rSAA4* to a highly conserved exon of *AY325132* ([Fig. 1](#f0005){ref-type="fig"}D) was performed using the Marathon rat brain cDNA as template. We observed no PCR-product indicating that these read-through mRNAs are not expressed in rat brain.

Next we analyzed *rSAA4* mRNA expression in various organs/tissues revealing highest expression in liver, lung, heart, spleen and kidney ([Fig. 2](#f0010){ref-type="fig"}A). This is comparable to expression patterns in the mouse [@b0055]. Injection of LPS did not alter *rSAA4* mRNA expression levels in all organs/tissues investigated ([Fig. 2](#f0010){ref-type="fig"}A).

Due to the striking homology of rSAA4 with hSAA4/mSAA4 ([Supplemental Fig. I](#s0090){ref-type="sec"}), an antibody raised against the C-terminal portion (that differs from SAA1/2) of hSAA4 was used. The antiserum recognizes non-glycosylated hSAA4 (14-kDa [@b0090], [Fig. 2](#f0010){ref-type="fig"}B \[lane 1\]) and non-glycosylated tagged hSAA4 (17-kDa [@b0085], [Fig. 2](#f0010){ref-type="fig"}B \[lane 2\], [Fig. 2](#f0010){ref-type="fig"}C \[lane 1\]), and a 14-kDa band in rat liver ([Fig. 2](#f0010){ref-type="fig"}C \[lane 2\]). This finding parallels data obtained in murine liver where no glycosylated mSAA4 protein is present. No immunoreactive bands for a 14-kDa protein were detected in other organs/tissues used for mRNA expression profiling ([Fig. 2](#f0010){ref-type="fig"}A).

We then investigated whether cytokine-treatment could modulate *rSAA4* transcription in McA-RH7777 cells. Highest induction (up to 9-fold) was found in IL-6-treated cells between 24 and 36 h. Other cytokines did not significantly alter *rSAA4* mRNA expression within 60 h ([Fig. 3](#f0015){ref-type="fig"}A). In contrast to the in vivo situation ([Fig. 2](#f0010){ref-type="fig"}A), where *rSAA4* mRNA seems to be constitutively expressed, LPS-treatment significantly induced *rSAA4* mRNA in McA-RH7777 cells (up to 4-fold) at almost all time points.

As basal levels of *rSAA4* mRNA in McA-RH7777 cells are low, we failed to detect rSAA4 by Western-blots. Therefore a full-length rSAA4-GFP fusion protein was overexpressed. Fluorescence microscopy revealed predominant localization of this fusion protein in the ER ([Fig. 3](#f0015){ref-type="fig"}B).

Previous studies have shown that the C/EBP-family of transcription factors plays important roles in the expression of *rSAA1* [@b0100; @b0105]. As disruption of hepatic C/EBPα in mice is paralleled by massive down-regulation of *mSaa4* mRNA [@b0110] we hypothesized that a C/EBP-element could be responsible for *SAA4* mRNA expression in rats. To investigate the regulation of the *rSAA4* gene we performed in silico promoter analysis of a region approx. 3000 bp upstream of the start codon using the Genomatix software [@b0115], predicting five C/EBP-elements ([Fig. 4](#f0020){ref-type="fig"}A); two are far distal from the start codon, whereas three others are located more proximal (\<1.200 bp). To test the activity of these elements we cloned a series of promoter constructs in a Luciferase-reporter vector ([Fig. 4](#f0020){ref-type="fig"}A). Deleting the three most proximal C/EBP-elements between −888 and −1167 bp (construct A) leads to reduced Luciferase-activity by approx. 90% ([Fig. 4](#f0020){ref-type="fig"}B). This suggests that the BOX (containing C/EBP-element-1/-2/-3 flanked by FAST and HOXF sites) is required for maximal promoter activity. To investigate the proximal elements C/EBP-element-1/-2/-3 within the BOX in more detail we surveyed truncation constructs for their capacity to regulate Luciferase activity. A proximal segment containing a single C/EBP-element-1 (+44 to −1084 bp, construct B) was able to evoke increased Luciferase activity \>2-fold in comparison to the control vector ([Fig. 4](#f0020){ref-type="fig"}B). Of note, we detected an additional increase in Luciferase activity (approx. 50%) in an even shorter proximal promoter fragment containing HOXF but no predicted C/EBP-element-1 (+44 to −932 bp, construct E, data not shown). The promoter fragment containing C/EBP-element-1 and -2 (+44 to −1113 bp, construct C) exhibited a significant increase over construct B (approx. 3.9-fold over pGL3). A promoter fragment containing all three proximal C/EBP-elements plus additional ∼1000 bp (+44 to −2449 bp, construct D) showed increased Luciferase-activity compared to pGL3 but decreased activity compared to construct B/C, indicating binding of potential repressive factor(s) between −1114 and −2449 bp. In summary, Luciferase assays suggest a strict requirement of the BOX-sequence for *rSAA4* promoter activity and argue for a positive effect of the predicted proximal C/EBP-elements in McA-RH7777 cells.

4. Discussion {#s0080}
=============

In contrast to humans, mice and other mammals, no A-SAA protein has been found to be associated with acute-phase HDL isolated from rats [@b0120]. Meek and Benditt [@b0120] reported two *SAA*-related genes (*rSAA1*, *rSAA2*) with striking homology to human and murine *SAA1/2*. Both genes were upregulated in the liver but not in extrahepatic tissues in response to LPS. However, *rSAA1/2* mRNA lack a sequence coding for ∼50-*aa* of the N-terminus of the predicted A-rSAA protein. Thus, it is obvious that rats, lacking A-SAA, do not develop secondary reactive AA amyloidosis [@b0120]. Although *rSAA3* mRNA has been identified [@b0120], it is still unknown whether rats do express SAA4 mRNA and protein. We here characterized a novel *SAA4* gene in the rat.

Basically, the exon/intron structure of *rSAA4* is similar to *hSAA4* and *mSaa4*. In addition to the 5′UTR and signal peptide, the complete sequence encoding 1--112-*aa* (as found in humans and mice) was determined. However, observations that the maximal 5′UTR exceeds the published rat RefSeq for *rSAA4* ([NM_001009478.1](ncbi-n:NM_001009478.1){#ir040}) by 90 bases (containing a GA-dinucleotide tandem repeat with 23-repeats) is unique. This tandem repeat is only present in the rat genome. Different repeat numbers found in rat ESTs (18- and 22-repeats) and also in our cloned 5′RACE products (9- and 10-repeats) indicate that this tandem repeat might be a result of different allelic variations. Whether the length of this repeat modulates rSAA4 expression remains to be elucidated.

The regulation of acute-phase genes in the rat by inflammatory mediators represents an excellent model to study the interplay between transactivators and transrepressors on inducible gene control [@b0125]. The control of eukaryotic gene transcription involves positive/negative regulatory mechanisms, and various transcription factors (primarily C/EBPs) have been reported to modulate mRNA expression of *A-SAA* [@b0005]. Several lines of evidence prompted us to study expression of *rSAA4* as well as its potential transcriptional inducers, namely C/EBP. First, when treated with LPS, *Saa1* and *Saa2* mRNA levels were not upregulated in the liver of C/EBPα-deficient compared to wild-type mice [@b0130]. Second, specific disruption of hepatic C/EBPα in mice led to an almost complete reduction of *Saa4* mRNA compared with that observed in floxed-mice [@b0110]. Third, NF-κB- and C/EBP-like transcription factors act as primary inducers of *rSAA1* mRNA in the liver [@b0100; @b0105].

Although NF-κB binding sites are present in the promoter region of *rSAA4*, we focussed on C/EBP-binding sites. Using specific deletions in the promoter region, we identified three most proximal C/EBP-elements (between −888 and −1167 bp) that mediate expression of *rSAA4* in McA-RH7777 cells. Members of the C/EBP family act as pivotal regulators of cellular differentiation, terminal function, and response to inflammatory insults due to cytokine activation. Although IL-6 (in contrast to other cytokines) promotes *rSAA4* expression in rat hepatoma cells even at early time points ([Fig. 3](#f0015){ref-type="fig"}A), mRNA levels of individual members of the C/EBP-family (*C/EBPα* and *C/EBPβ*) were not affected ([Supplemental Fig. II](#s0090){ref-type="sec"}). This raises the possibility that NF-κB could act in concert with C/EBP to promote *rSAA4* activation. Alternatively, transcription factor YY1 may modulate *rSAA4* transcription by binding to a site overlapping with the NF-κB-binding site [@b0135]. AP-2 acts as a negative regulator in extrahepatic tissues but promotes liver-specific *rSAA1* expression [@b0140]; in addition, a proximal AP-2 site in combination with the NF-κB-binding site is essential for *rSAA1* promoter activity [@b0125]. Whether these different modes of action, as previously reported for *rSAA1* [@b0135], are also operative for *rSAA4* is currently unknown. However, our data showing even stronger Luciferase activation with a short construct devoid of the three proximal C/EBP-sites (not shown) and decreased activity with construct D (containing all three C/EBP-sites plus additional ∼1000 bp) compared to construct C (containing only two C/EBP-sites) argue for the involvement of additional activators and repressors, respectively.

To sum up, we demonstrate for the first time the presence of a novel member of the SAA4 family on mRNA and protein level, previously not identified in the rat. The rSAA4 protein is expressed in the liver as a non-glycosylated protein, comparable to mice.

Appendix A. Supplementary data {#s0090}
==============================

Supplementary data 1

Supported by the Austrian Science Fund (FWF-Austria) P19074 and SFB F3004 and F3007.

![*Gene structure of rSAA4*. (A) Rat *SAA4* mRNAs (*BC088188*, *AY325132*, *AY325161*) from GenBank® (<http://www.ncbi.nlm.nih.gov/genbank/>) are shown; thin grey squares (![](fx1.gif)) represent untranslated regions, broad grey squares (![](fx2.gif)) represent translated regions; intronic sequences are shown as thin black lines. Arrowheads indicate orientation of the gene. (B) Exon/intron structure of spliced ESTs published in the UCSC Genome Browser with the most extended 5′UTR (FQ107900) and 3′UTR region (EX492688) of *rSAA4* are shown. (C) Schematic representation of results obtained by RACE: 3′RACE product extends the 5′UTR of *EX492688* with 574 bases; that confirms the 5′UTR of *BC088188*; 5′RACE product extends the 3′-region of *BC088188* and confirms the 3′UTR represented by the spliced EST FQ107900. (D) The predicted PCR-product for primers spanning from the first coding exon of *rSAA4* reaching to a primer located 2 exons upstream of *rSAA4* within a conserved exonic region of *AY325132*. PCR-amplification of the 190 bp product was unsuccessful using rat Marathon cDNA as template and standard PCR programs. (E) Deduced full-length *rSAA4* from RACE is shown: thin black squares (![](fx3.gif)) represent untranslated regions, broad black squares (■) represent translated regions, intronic sequences are shown as thin black lines. The location of the GA-dinucleotide repeat (GA)~n~ within the 5′UTR of *rSAA4* is indicated below. (F) Partial 5′UTR of the *SAA4* gene in different mammalian species (i.e. *rSAA4*, *mSAA4*, and *hSAA4*): note the GA-dinucleotide tandem repeat is only present in the rat genome. The UCSC Genome Browser [@b0145] was used.](gr1){#f0005}

![*Expression of rat and human SAA4*. (A) Organs/tissues of control and LPS-treated rats (48 h) were excised, RNA was isolated, reverse transcribed and subjected to qPCR. Absolute *rSAA4* mRNA expression was determined with a calibration curve. Non-treated (controls, *n* = 5) and LPS-treated rats (*n* = 7; except for lung, heart, thymus, kidney \[*n* = 6\] and liver \[*n* = 5\]). Equal amounts of non-glycosylated recombinant hSAA4 (r-hSAA4) (B) and tagged-r-hSAA4 (tr-hSAA4) (B/C) or protein lysate (65 μg/lane) from rat liver (C) was subjected to Western-blot analysis using anti-human SAA4-peptide antiserum as a primary antibody. One representative experiment is shown.](gr2){#f0010}

![*Cytokine- and LPS-induced expression of rSAA4 in McA-RH7777 cells and intracellular localization of rSAA4-GFP-fusion protein*. (A) Cells were treated with cytokines or LPS for indicated time periods. RNA was isolated, reverse transcribed and subjected to qPCR. *rSAA4* expression levels were normalized to *rGAPDH* (^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001). Results are derived from two independent experiments performed in duplicate. ns, non-stimulated cells. (B) Intracellular localization of the GFP-tagged rSAA4 protein by confocal laser-scanning microscopy: green (GFP), red (ER or Mito-Tracker®), yellow (colocalization). The bar represents 5 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr3){#f0015}

![*Luciferase assay of rSAA4 promoter constructs in McA-RH7777 cells.* (A) Overview of the *rSAA4* promoter (+44 and −3293 bp relative to the start codon) and the *rSAA4* promoter deletion constructs. Deletion of the BOX (between −888 and −1167 bp; containing the three proximal C/EBP response elements and flanked by FAST and HOXF binding sites) resulted in the generation of construct A. Construct B--D contained the one, two, and three most proximal C/EBP binding sites, yielding starting points at −1084 (construct B), −1113 (construct C), and −2449 (construct D), respectively. (B) Cells were transfected with 2 μg of the respective *rSAA4* promoter construct and with 4 ng of the control plasmid pRL-TK. Twenty-four hours after transfection cells were lysed and Firefly and Renilla luminescence was quantified. Results are derived from four (construct B/D) or three (construct A/C) independent experiments performed in triplicate. Results were normalized to the empty Luciferase vector (pGL3; ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001).](gr4){#f0020}
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